NGLY1 Natural History

Investigation of NGLY1 Deficiency Movement Disorder & Clinical Features

N-glycanase 1 (NGLY1) Deficiency (OMIM #615273) is an ultra-rare, autosomal recessive disorder caused by loss of function variants in NGLY1 gene. The multisystemic disorder is characterized by five key features: (1) global developmental delay and/or intellectual disability, (2) a (primarily) hyperkinetic movement disorder (3) transient elevation of liver transaminases (4) (hypo)- alacrima and (5) peripheral neuropathy. The condition was first reported in 2012 and thus comprehensive characterization of the disease, especially its unique movement disorder, continues to be described.

The hyperkinetic movement disorder in NGLY1 Deficiency is highly complex and has been qualitatively described to include choreiform, athetoid, dystonic, myoclonic, action tremor, and dysmetric movements. These descriptors apply to both lower and upper limb movement in individuals with NGLY1 Deficiency.

Preliminary results indicate that NGLY1 Deficiency is associated with a myriad of movement control problems and range from being unable to perform certain arm movements or walk to behaviors that appear quite similar to age-matched neurotypical individuals. Preliminary results suggest that when reaching for objects, arm motion patterns tend to display unusual joint and hand trajectories, relative to neurotypical individuals, thereby decreasing their effectiveness/efficiency. During gait, range of joint motion, particularly at the knee, was often significantly reduced combined with evidence of leg movement asymmetry. Additionally, preliminary results indicate that there is low frequency tremor, particularly in the upper limbs, that tends to decline during arm acceleration. These preliminary findings, if confirmed in a larger sample, provide entryways to the understanding of how NGLY1 Deficiency impacts movement control and thereby may serve both as diagnostic and therapeutic endpoints for physicians and therapists.

The purpose of this natural history study in NGLY1 Deficiency is to collect longitudinal measurements of movement concurrently with clinical and biomarker measures to aid in the development in end points for future therapeutic trials.

Study Overview

• Status: Recruiting
• Conditions: NGLY1 Deficiency

Detailed Description

This is a single center, longitudinal descriptive study of the concurrent movement disorders and neurodevelopmental and clinical status in children with NGLY1 Deficiency.

Subjects will be recruited through the Grace Science Foundation (GSF), a patient advocacy organization focused on NGLY1 Deficiency. GSF will post on social media institutional review board (IRB)-approved information regarding the study. We will gather (1) detailed standardized motor function measures, (2) blood samples for laboratory analysis, and (3) clinical measures including growth and neurodevelopmental assessments.

Assessments will occur at four time points: Visit 1 (baseline), Visit 2 (6 months ± 4 weeks), Visit 3 (12 months ± 4 weeks) and Visit 4 (24 months ± 4 weeks).

Clinical and laboratory measures will be collected to aid in analysis and to document factors which may impact the movement disorder as well as overall disease progression.

Standard descriptive statistics will be used to evaluate all demographic and other clinical subject information.

The clinical data will be analyzed by a child neurologist, developmental pediatrician, or neuropsychologist by standard descriptive statistics (e.g. mean and standard deviation, T-tests). Movement data from the sub-domains of Bayley and Vineland, GMFM-88 and GMFCS, E & R will be compared against normative data and against longitudinal data obtained. Analyses will be performed at baseline evaluation, as well as the second and third timepoints.

STUDY ASSESSMENTS:

• Physical Examination: A physical examination will include, at a minimum, assessments of the cardiovascular, respiratory, gastrointestinal, skin, and musculoskeletal systems.
• Height, weight, and head circumference will also be measured and recorded.
• Medical History
• Neurological Examination
• Ophthalmologic Examination
• Gross Motor Function Measure (GMFM-88):The GMFM-88 is an assessment tool designed to measure changes in gross motor function over time (Harvey 2017) or with intervention in children with cerebral palsy.
• Gross Motor Function Classification System, Expanded & Revised (GMFCS, E & R):The GMFCS - E&R is a 5-level classification system that describes the gross motor function of children and youth on the basis of their self-initiated movement with particular emphasis on sitting, walking, and wheeled mobility; it was developed for children with cerebral palsy and has been used with other neuromuscular pediatric diseases.
• Communication Function Classification System (CFCS): The purpose of the CFCS is to classify the everyday communication performance of an individual with cerebral palsy into one of five levels
• Bayley Scales of Infant and Toddler Development - Fourth Edition (BSID-4): The BSID-4 (Bayley 2019) is designed for infants and toddlers from 16 days to 42 months of age, but due to the level of impairment in individuals with NGLY1 Deficiency, the scale will be utilized independent of the age of the subject so age-independent normative scores will be analyzed.
• Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV): The WPPSI-IV will be performed at each visit if subjects are too highly functioning for the Bayley and have aged out. The WPPSI-IV uses subtests and composite scores to assess a student's general intellectual ability and cognitive functioning based on their test performance and chronologic age.
• Vineland Adaptative Behavior Scale - Version 3 (Vineland 3):The Vineland-3 measures adaptive functioning, specifically communication, daily living skills, socialization, and motor skills
• Clinician Global Impression of Severity (CGI-S) and Clinician Global Impression of Change (CGI-C):The CGI-S, adapted for NGLY1 Deficiency, assesses severity of the subject's symptoms of NGLY1 Deficiency.
• Caregiver Global Impression of Severity (CaGI-S) and Caregiver Global Impression of Change (CaGI-C):The CaGI-S, adapted for NGLY1 Deficiency, assesses severity of the subject's symptoms of NGLY1 Deficiency based on the caregiver's impression.
• Blood Draw: Plasma GNA Biomarkers and Liver Function Test

• Study Type: Observational
• Enrollment (Estimated): 15

Contacts and Locations

• Study Contact: Name: Bernhard Suter, MD; Phone Number: 832-822-7388; Email: suter@bcm.edu

Study Locations

• United States
  • Texas
    • Houston, Texas, United States, 77030
      • Recruiting
      • Texas Children's Hospital
      • Contact: Bernhard Suter, MD; Phone Number: 832-822-1779; Email: suter@bcm.edu
      • Sub-Investigator: Gary Clark, MD
      • Sub-Investigator: Holly Harris, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

N-glycanase 1 (NGLY1) Deficiency (OMIM #615273) is an ultra-rare, autosomal recessive disorder caused by loss of function variants in NGLY1 gene. The multisystemic disorder is characterized by five key features: (1) global developmental delay and/or intellectual disability, (2) a (primarily) hyperkinetic movement disorder (3) transient elevation of liver transaminases (4) (hypo)- alacrima and (5) peripheral neuropathy.

Description

Inclusion Criteria:

• Individuals aged 2 to 25 years with a confirmed molecular diagnosis of NGLY1 Deficiency.
• Subjects and/or their parents or legal guardians signed a written informed consent and assent (if applicable).

Exclusion Criteria:

• Prior or current participation in a therapeutic trial for NGLY1 Deficiency (note that neither the plan for future participation in an interventional trial nor participation in previous pilot study preclude entering this trial).

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
N-glycanase 1 (NGLY1) Deficiency

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To characterize movement and gait disorder	in a larger cohort of NGLY1 Deficiency subjects	24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To determine the progression of movement disorder parameters	via collection of longitudinal data	24 months
To describe associations between movement disorder parameters with relevant clinical measures	such as neurodevelopmental assessments and laboratory values	24 months

Collaborators and Investigators

• Sponsor: Baylor College of Medicine
• Collaborators: Grace Science Foundation
• Investigators: Principal Investigator: Bernhard Suter, MD, Baylor College of Medicine

Study record dates

Study Major Dates

• Study Start (Actual): February 27, 2023
• Primary Completion (Estimated): February 23, 2025
• Study Completion (Estimated): February 23, 2025

Study Registration Dates

• First Submitted: November 2, 2023
• First Submitted That Met QC Criteria: November 3, 2023
• First Posted (Estimated): November 8, 2023

Study Record Updates

• Last Update Posted (Estimated): November 8, 2023
• Last Update Submitted That Met QC Criteria: November 3, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: H-49928

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No